GHK-Cu is sold in two forms that share a name and little else. The cream and gel versions go on skin and have a small human trial record. The injected version has no published human dosing at all. This page keeps the two apart, lists every concentration and amount I could trace, and says which ones come from a trial, which from a rodent, and which from a web page that cites nothing.
Ask PeptideBlog about any peptide
Quick answer: GHK-Cu has no FDA label dose and no published human dose for injection. Human trials exist only for skin products, and the papers I could read often omit the concentration; the one stated strength was a 0.4% cream that did no better than vehicle.[3][4] Online, injected GHK-Cu is most often reported at 1 to 2 mg once a day, or 3 to 5 injections a week, for 4 to 8 weeks.[19][20] Those figures trace to wiki and community pages, not to a trial. Topical figures range from a safety-review use level of less than 10 ppm to community serums of 1 to 3%.[7][20]
Figures on this page summarize amounts and schedules reported in published research, prescribing information or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Every studied or reported GHK-Cu amount at a glance
Topical strengths are percentages of a cream, gel or serum. Injected amounts are milligrams per injection. They are different quantities in different parts of the body, so they sit in two tables and are never converted into each other anywhere on this page.
Topical and cosmetic products
Swipe the table sideways to see every column.
| Source | Population | Route | Amount or concentration | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Cosmetic Ingredient Review safety assessment | Cosmetic users (use data, not a trial) | Topical, leave-on and rinse-off products | Reported use “less than 10 ppm” for the ingredient group that includes copper tripeptide-1 (10 ppm is 0.001%) | Not stated | Not stated | Expert panel safety review of use and laboratory data; Tier 4[7] |
| Mulder 1994, diabetic neuropathic foot ulcers | Adults with diabetic foot ulcers (group sizes not in abstract) | Topical gel | GHK-Cu gel, daily metered dose; concentration not in the abstract | Daily | Not consistently reported | Published human clinical trial (Tier 1)[3] |
| Bishop 1992, venous stasis ulcers | 86 evaluable patients | Topical cream | 0.4% tripeptide copper complex cream | Not consistently reported | Not consistently reported | Published human clinical trial (Tier 1). No difference from vehicle[4] |
| Miller 2006, laser-resurfaced skin | 13 completers | Topical | Concentration not in the abstract | Not consistently reported | Not consistently reported | Published human clinical trial (Tier 1)[5] |
| Facial cream studies summarized in a 2015 review | 71 women; 41 women (eye cream); 67 women aged 50 to 59 | Topical cream | Concentrations not stated in the review | Twice daily reported for the 67 woman study | 12 weeks | Origin unclear: primary papers not found in PubMed; company-affiliated review[2] |
| Hostynek 2010, human skin in the lab | Excised human skin (no people treated) | Topical, diffusion cell | 0.68% aqueous copper as the tripeptide cuprate diacetate | Single application | 48 hours | Laboratory research (Tier 4)[6] |
| Registry record NCT07437586, 5 mm punch wounds | 60 healthy adults (planned) | Topical GHK-Cu gel versus vehicle | Concentration not stated in the registry record | Once daily | 14 days of treatment, 21 days of observation | Registered human trial; no results (Tier 2)[16] |
| Wiki dosing page, topical table | Not applicable | Topical | “Cosmetic” 0.01 to 0.1%; “premium” 0.1 to 1%; wound 0.5 to 2%; hair 0.01 to 0.1%; after microneedling 0.1 to 1% | Not stated in the table | Not stated in the table | Community reported (Tier 6); the sources listed in the table are labels such as “small clinical studies” with no references[19] |
| Wiki community page (90 reports) | Self-reported users | Topical serum | 1 to 3% serum; 1 to 2% scalp use for hair | Once daily | 8 to 12 weeks | Community, vendor or clinic reported (Tier 6)[20] |
Injected and other routes
Swipe the table sideways to see every column.
| Source | Population | Route | Amount | Frequency | Duration | Evidence category |
|---|---|---|---|---|---|---|
| Published human injection trials | None identified | Injection | No established or reliably sourced dosing information was identified. | Not applicable | Not applicable | No evidence category applies[18] |
| Pickart reviews, human estimate | Extrapolated from rats | Not stated for the human figure | “About 100 to 200 mgs” of GHK, written as an estimate that “may overestimate” | Not stated | Not stated | Author estimate built from animal data, Tier 3; not a tested human dose[1][2] |
| Wiki dosing page | Community and practitioner use | Subcutaneous | 1 to 2 mg per injection | Once daily, or 3 to 5 injections per week | 4 to 8 weeks on, 2 to 4 weeks off | Community, vendor or clinic reported (Tier 6). Page names “practitioner protocols and community use” and lists no references[19] |
| Wiki community page (90 reports) | Self-reported users | Subcutaneous | “Most common dose is 2 mg daily” | Daily, or 3 to 5 times per week | 4 to 8 weeks on, 2 to 4 off | Community, vendor or clinic reported (Tier 6)[20] |
| Peptidepedia dosage page | Pharmacist-authored site that carries advertising | Subcutaneous | Start 0.5 mg; standard 0.5 to 1 mg | Daily | 4 to 8 weeks, then a 2 to 4 week break | Practitioner reported (Tier 5). Six references are listed but not matched to these figures[21] |
| Peptide Dossier dosage guide | Educational site that states it does not sell peptides | Subcutaneous | Rejects the 1 to 3 mg daily range and “2 mg optimal” as unsupported | Rejects 8 to 12 week cycles | Not applicable | Conflicting reports. The guide sides with the evidence gap[22] |
| Rat and mouse studies | Rodents | Intraperitoneal, intra-articular, intranasal | See the animal table; amounts are per kilogram or per milliliter and are not human doses | Varies | Days to weeks | Published animal research (Tier 3). Never convert to a human amount[10][11][12] |
There is no FDA-approved GHK-Cu drug, so no prescribing information exists to anchor either table. Cosmetic GHK-Cu is sold under the ingredient name Copper Tripeptide-1.[7][28] Wiki figures come from the Peptide Protocol Wiki, a community-run reference. Studies were read at abstract level unless the text below says otherwise.
Where these figures come from
The most-reported injected figure is 1 to 2 mg under the skin once a day, and “2 mg daily” is described as the most common dose among 90 community reports collected by the Peptide Protocol Wiki.[19][20] That wiki says its source is “practitioner protocols and community use” and lists no references. Peptidepedia, a pharmacist-authored site, gives a lower band of 0.5 to 1 mg daily, also without tying the numbers to a paper.[21] I found no trial that tested 1 or 2 mg per injection in people. The figure appears to be a convention that spread, not a result.
The only published human-scale injected number comes from Loren Pickart, who is credited with isolating GHK from human albumin in 1973.[28] His 2014 and 2015 reviews, written with two co-authors under a Skin Biology research and development affiliation, estimate that “about 100 to 200 mgs of GHK” might produce therapeutic actions in humans, and then add that “even this may overestimate.”[1][2] That is arithmetic scaled up from rat injections, with no human test behind it, and it sits far from the 1 to 2 mg that circulates today.
On the skin side, the strongest numbers are small. The Cosmetic Ingredient Review expert panel reports use at “less than 10 ppm” for the ingredient group that includes copper tripeptide-1.[7] Ten parts per million is 0.001%. The wiki says most commercial products hold 0.01 to 0.1%, and its community page describes serums of 1 to 3%, a spread of up to three thousandfold.[19][20] The only trial strength I could read, 0.4%, did nothing better than vehicle in venous ulcers.[4]
Weight-based dosing does not exist for GHK-Cu in any human source I opened. Rodent amounts per kilogram appear in the animal table below and should not be turned into human amounts.[11][12] The wiki publishes its own conversion from animal data and calls it “purely academic,” which is the right reading of it.[19]
Copying is likely. The wiki and Peptidepedia agree on 4 to 8 week cycles with a 2 to 4 week break, but neither shows where the cycle came from, so their agreement counts once at most.[19][21] Peptide Dossier, an educational site that states it sells nothing, reviewed the same circulating claims and rejected the 1 to 3 mg daily range, the “2 mg optimal” label and the 8 to 12 week cycles as unsupported.[22]
Technical identity
GHK is a three amino acid chain, glycine, histidine and lysine, that occurs in human blood plasma. GHK-Cu is that chain bound to a copper(II) ion. Pickart reports plasma levels of about 200 ng/mL at age 20 and about 80 ng/mL at age 60, which underlies the “declines with age” claim.[28] Most of the identifiers below come from a single secondary source, so treat them as pending confirmation from a chemical database.
Swipe the table sideways to see every column.
| Property | Information |
|---|---|
| Primary name | GHK-Cu, glycyl-L-histidyl-L-lysine copper(II) complex. Cosmetic name: Copper Tripeptide-1[7][28] |
| Peptide sequence | Gly-His-Lys (GHK) |
| Length | 3 amino acids |
| Molecular formula | GHK free peptide C14H24N6O4. Copper complex C14H22CuN6O4. Source: Wikipedia only[28] |
| Molecular weight | GHK free peptide 340.38 g/mol[28]. Copper complex: Not reliably established |
| CAS Registry Number | GHK 49557-75-7. GHK-Cu 89030-95-5. Source: Wikipedia only[28] |
| PubChem CID | GHK 342538. GHK-Cu 378611. Source: Wikipedia only[28] |
| UNII | Not reliably established (a registry entry under 6BJQ43T1I9 exists but could not be opened to confirm which form it covers) |
| DrugBank ID | Not reliably established |
| Plasma half-life | About 0.5 to 1 hour, as stated in a Pickart review; not confirmed by an independent human study[1] |
| Peptide class and target | Copper-binding tripeptide. Reported to bind copper with an affinity close to albumin and to influence wound repair and tissue remodeling genes in cell studies at about 1 to 10 nM[1] |
| Developer or originator | Isolated by Loren Pickart in 1973[1][28]. No approved drug product |
| Development status | Cosmetic ingredient; unapproved as a drug. See regulatory status below |
More background sits on the GHK-Cu research entry and the entry for the free GHK peptide. Pickart tested a roughly even mix of GHK and GHK-Cu in many experiments, so some “GHK-Cu” results may not be copper-complex results alone.
The copper complex molecular weight is left blank on purpose: no source I opened states it, and a derived figure would be my arithmetic, not a verified value.
Detailed human data
What the human studies tested
Swipe the table sideways to see every column.
| Study | Design | Population | Regimen | Result |
|---|---|---|---|---|
| Mulder 1994 | Multicenter randomized, evaluator blinded, placebo controlled | Diabetic neuropathic foot ulcers; n not in abstract | GHK-Cu gel, daily metered dose, versus vehicle | Median wound area closure 98.5% versus 60.8% (p below 0.05). Ulcers over 100 mm²: 89.2% closure versus a 10.3% increase in wound size on vehicle (p below 0.01). Infection 7% versus 34%.[3] |
| Bishop 1992 | Randomized, evaluator blinded | Venous stasis ulcers, 86 evaluable | 0.4% copper complex cream versus vehicle, plus silver sulfadiazine 1% arm | No difference from vehicle. Silver sulfadiazine reduced ulcer size more.[4] |
| Miller 2006 | Randomized, circumoral laser resurfacing | 13 completers | Skin regimen with or without GHK-Cu; strength not in abstract | Everyone improved. No significant objective difference between groups. Questionnaire favored GHK-Cu for overall skin quality (P = .04).[5] |
| Facial studies in the 2015 review | Reported by a company-affiliated author | Women in 12 week facial and eye cream studies | Creams of unstated strength | The review reports, for a thigh biopsy comparison, collagen increases in 70% of GHK-Cu treated skin, 50% with vitamin C and 40% with retinoic acid. I could not locate the primary papers.[2] |
| Tanaka 2018 | Case series, 18,918 men | Hair loss clinic; combination protocol | Monthly injection of a solution holding about a dozen ingredients including copper tripeptide, plus oral and topical drugs | Minor complications in 4.2%. The copper peptide cannot be separated from the other ingredients, and its amount is not given.[15] |
The diabetic foot ulcer trial is the best-known human result. In Mulder 1994, a multicenter randomized, evaluator blinded trial, a GHK-Cu gel applied as a daily metered dose closed a median 98.5% of wound area against 60.8% with vehicle gel, and infections were 7% versus 34%.[3] The abstract does not give the gel strength or how many people were in each arm, and the chart below shows only what the abstract reports.[3]
Two other controlled trials are less flattering. Bishop 1992, in 86 evaluable patients with venous ulcers, found a 0.4% copper complex cream no different from vehicle, and silver sulfadiazine 1% reduced ulcer size more.[4] In Miller 2006, 13 people completed a randomized comparison of skin regimens with or without GHK-Cu after laser resurfacing. Everyone improved, objective measures did not differ between groups, and the questionnaire favored GHK-Cu for overall skin quality (P = .04).[5] The facial studies that underpin most cosmetic claims are summarized in Pickart’s own 2015 review; I could not find the primary reports on PubMed.[2]
One laboratory test shows how much copper crosses skin. In excised human skin, a 0.68% copper solution as the tripeptide complex moved 136.2 ± 17.5 µg/cm² of copper through the tissue over 48 hours, and 82 ± 8.1 µg/cm² stayed in it.[6] That experiment measured copper, and no person was treated. It says nothing about injected dosing, where the skin barrier is bypassed.
Two registry entries are worth knowing. NCT07437586 plans to test a topical GHK-Cu gel against vehicle on small punch wounds in 60 healthy adults, once daily for 14 days, with time to skin closure over 21 days as the main outcome.[16] The record gives no concentration, and the sponsor, Hudson Biotech, has several registrations with identical start dates and a single site, so I would not read it as a mature development program. NCT07706361 is a not yet recruiting study of a wearable patch and blood GHK levels, not an injection.[17]
For injection, the answer is short. No published human study of injected GHK-Cu has reported its safety or effectiveness, as an NPR report in September 2026 put it, citing experts including Dr. Warren Ladiges of the University of Washington and Dr. David Goldberg of Mount Sinai.[18] Ladiges is also a co-author of the mouse preprint described below.[12] No established or reliably sourced dosing information was identified.
Animal research amounts
Rodent studies use amounts per kilogram or per milliliter. They are shown with their original units, and none should be read as a human amount.
Swipe the table sideways to see every column.
| Research objective | Species or model | Amount studied | Frequency | Duration | Route | Source |
|---|---|---|---|---|---|---|
| Ischemic wounds | Rat, 24 animals | 2% topical gel, daily | Daily | 13 days | Topical | Canapp 2003: wound area fell 64.5% (copper tripeptide), 45.6% (vehicle), 28.2% (control)[8] |
| Wound healing | Rabbit, 18 animals | Concentration not in abstract | Daily | 21 days | Topical | Cangul 2006[9] |
| ACL reconstruction | Rat, 72 animals | 0.3 or 3 mg/ml | Weekly | 4 weeks, starting at week 2 | Intra-articular | Fu 2015: benefit at 6 weeks but not at 12[10] |
| Bleomycin lung fibrosis | Mouse | 0.2, 2 and 20 µg/g/day in 0.5 ml PBS | Alternate days | Not in abstract | Intraperitoneal | Ma 2019[11] |
| Aging and memory | Mouse, 20 to 21 months old | 15 mg/kg | Not consistently reported | 5 days (IP) or 8 weeks (intranasal) | Intraperitoneal or intranasal | Mazzola 2026 preprint, not peer reviewed; intranasal gave sustained benefit[12] |
| Scald wounds | Mouse | GHK-Cu in liposomes; amount not in abstract | Not in abstract | Healing time 14 days | Topical | Wang 2017[13] |
| Diabetic wounds | Rat | Biotinylated GHK in a collagen matrix; amount not in abstract | Not in abstract | Not in abstract | Topical matrix | Arul 2006[14] |
| DSS colitis | Mouse | Dose not in abstract | Not in abstract | Not in abstract | Not in abstract | Mao 2025[29] |
The most relevant finding for people who inject is the Pickart point that route and schedule matter. His 2014 review says giving rats ten intraperitoneal injections a day cut the needed dose about a hundredfold.[1] A 2026 preprint in aged mice that is not yet peer reviewed found that 15 mg/kg given intraperitoneally for 5 days and intranasally for 8 weeks produced different molecular programs, and only the intranasal course gave a sustained improvement in a memory task.[12] In the knee study, weekly intra-articular injections helped at 6 weeks but the benefit was gone by 12.[10] Those are the kinds of results that would need human dose finding, which has not been done.
Practitioner and community-reported protocols
These are the figures people actually search for. They are reproduced as the pages state them. None comes from a clinical trial, and none should be read as validated guidance.
Swipe the table sideways to see every column.
| Reported objective | Amount reported | Frequency | Duration | Route | Source type | Source |
|---|---|---|---|---|---|---|
| General injectable protocol | 1 to 2 mg per injection | Once daily, or 3 to 5 times per week | 4 to 8 weeks on, 2 to 4 weeks off | Subcutaneous | Community, vendor or clinic reported (Tier 6) | Peptide Protocol Wiki dosing page[19] |
| Most common reported dose | 2 mg | Daily | 4 to 8 weeks on, 2 to 4 off | Subcutaneous | Community, vendor or clinic reported (Tier 6) | Same wiki, community page, 90 reports from Reddit r/Peptides, r/PeptideResearch and commercial sites[20] |
| Starting and standard | Start 0.5 mg; standard 0.5 to 1 mg | Daily | 4 to 8 weeks, then a 2 to 4 week break | Subcutaneous | Practitioner reported (Tier 5) | Peptidepedia[21] |
| Skin and cosmetic serum | 1 to 3% serum | Once daily | 8 to 12 weeks | Topical | Community, vendor or clinic reported (Tier 6) | Wiki community page[20] |
| Hair and scalp | 1 to 2% on the scalp; 0.01 to 0.1% in the wiki table | Not consistently reported | Not consistently reported | Topical | Community, vendor or clinic reported (Tier 6) | Wiki community and dosing pages[19][20] |
| After microneedling | 0.1 to 1% (table); 1 to 2% (community reports) | Not consistently reported | Not consistently reported | Topical | Community, vendor or clinic reported (Tier 6) | Wiki dosing and community pages[19][20] |
| Wound care | 0.5 to 2% (labeled “preclinical” in the wiki table) | Not consistently reported | Not consistently reported | Topical | Community, vendor or clinic reported (Tier 6) | Wiki dosing page[19] |
The wiki shows how its numbers turn into syringe volumes with a stated concentration: a 50 mg vial mixed with 2 mL of liquid is 25 mg/mL, so a 2 mg dose is 0.08 mL, or 8 units on a U-100 syringe.[19] The arithmetic is correct for that example. The concentration is whatever the person chooses to mix, so the same 2 mg would be a different volume in another vial. Peptide Dossier warns of a common unit error, the claim that 1 mg sits at each U-100 mark. At 1 mg/mL each mark is 0.01 mL, or 0.01 mg, which is 10 mcg.[22] The units guide and the reconstitution calculator do this math with no preset dose.
The wiki also recommends serum copper checks for people who inject and says to avoid GHK-Cu in Wilson’s disease, a disorder of copper handling.[19] Those are the wiki’s statements, not clinical guidance.

Escalation, timing, duration, routes
No source I found describes a titration ladder for GHK-Cu. The nearest thing is Peptidepedia’s suggestion to start at 0.5 mg, which is a start point, not a schedule.[21] Cycle patterns are all of one type: weeks on, then weeks off, with 4 to 8 on and 2 to 4 off the commonest wording.[19][20][21] Peptide Dossier objects to 8 to 12 week cycles because it could find no evidence for them.[22]
Routes in the record are topical, subcutaneous injection, intraperitoneal injection in rodents, intra-articular injection in rats, intranasal in mice, and microneedling plus topical, which is community-reported only. The half-life given by Pickart is about 0.5 to 1 hour.[1] Whether that supports once-daily or three-times-weekly injection has never been tested. For general injection technique, see the injection basics guide.
Combinations and stacks
Formally studied: the closest case is Tanaka 2018, a case series of 18,918 men where a monthly injection mix containing copper tripeptide and about a dozen other ingredients was one part of a protocol that also included oral finasteride and minoxidil. Minor complications occurred in 4.2%, and the copper peptide cannot be separated out.[15]
Mechanistically plausible: GHK-Cu and BPC-157 are both discussed for tissue repair. That is a mechanism-level argument, not a tested pairing. Community-reported: GHK-Cu appears inside multi-peptide mixes known by street names. The GHK-Cu and BPC-157 blend page, GLOW, KLOW and Wolverine pages cover what each name usually contains, and compositions differ by source. I found no sourced per-component amounts for any of them. A popular combination is not a validated one.
Side effects, quality and sourcing risks
For topical use, the Cosmetic Ingredient Review concluded that copper tripeptide-1 was safe in cosmetics at present practices of use and concentration.[7] The trial abstracts I read did not set out adverse event counts in a way I could report, other than Mulder’s lower infection rate.[3]
For injection, the human safety record is unpublished. The September 2026 NPR report quotes clinicians who say they have seen injection-site irritation, infections and elevated liver enzymes and copper levels in people who injected copper peptides, with no counts and no confirmation that the peptide caused them.[18] FDA has said compounded injectable GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities” and that human data are limited.[25] Immunogenicity means the body could make antibodies against the product or its contaminants.
A copper-specific concern is built in: the compound delivers copper along with the peptide, which is why the wiki mentions serum copper checks and Wilson’s disease.[19] Long-term injected exposure has not been studied. I did not find a published purity or sterility survey of GHK-Cu products, and the general issues of mislabeling, wrong concentration and contamination in unapproved peptide products are explained in the certificate of analysis guide. Products sold as research chemicals have no obligation to meet drug-quality rules.
Regulatory and development status
As checked on 2 November 2026, no GHK-Cu drug is FDA-approved. The FDA interim category list, updated 14 May 2026, shows “GHK-Cu (except for injectable routes of administration)” in Category 1.[24] FDA’s Category 2 page, which lists nominations withdrawn by the people who proposed them, shows “GHK-Cu (for injectable routes of administration)” with the immunogenicity concern quoted above.[25] The listing was removed in April 2026 after withdrawals, then restored for non-injectable routes after a nominator clarified that it had withdrawn only the injectable one.[24][25]
GHK-Cu is not among the six peptides in Appendix A of the HHS 503A enforcement discretion policy, which lists BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500.[26][27] NPR reported in September that FDA’s advisory committee is expected to take up injectable GHK-Cu in February.[18] One certification company’s page says an advisory committee has already recommended adding GHK-Cu to the 503A list; that conflicts with the FDA pages and the HHS appendix, so I do not repeat it as fact.[23] Skin-care GHK-Cu is sold as an over-the-counter cosmetic. The FDA peptide status page and the HHS policy explainer cover the categories in plain language.
For athletes, I searched a copy of the 2026 WADA prohibited list and found no GHK or copper peptide entry. The certification company’s page treats it as covered by the catch-all section for unapproved substances under USADA’s interpretation, a claim I could not confirm.[23]

What is not public
The public record lacks: any published human injection study; a dose-finding study of any kind; GHK-Cu concentrations in the Mulder and Miller trials; group sizes for Mulder; primary papers for the facial studies Pickart reviews; independent pharmacokinetics for injected or topical GHK-Cu in people; and a purity survey of products. Also unknown is whether the circulating 1 to 2 mg daily convention came from one person, one practitioner or the Pickart estimate in a different form. The reviews by Pickart and colleagues list an industry affiliation, which is worth weighing when reading them.[1][2]
Frequently asked questions
What is a typical GHK-Cu injection dose?
There is no established dose. The most-reported figure is 1 to 2 mg injected under the skin once a day, with 2 mg daily called the most common among 90 community reports. It comes from wiki and community pages that cite no trial.[19][20]
What is the GHK-Cu dosage chart for cycles?
Reported cycles are 4 to 8 weeks on and 2 to 4 weeks off, from the Peptide Protocol Wiki and Peptidepedia. Peptide Dossier rejected 8 to 12 week cycles as unsupported. None of these is a clinical schedule.[19][21][22]
How strong should GHK-Cu cream or serum be?
Sources disagree widely. A Cosmetic Ingredient Review figure is less than 10 ppm (0.001%), the one trial strength I could read was 0.4% and did no better than vehicle, and community pages report 1 to 3% serums.[4][7][20]
Has GHK-Cu been tested in humans?
Yes, on skin. Trials covered diabetic foot ulcers, venous ulcers and laser-resurfaced skin, with mixed results. No published human study of injected GHK-Cu was identified.[3][4][5][18]
How much did the best human trial use?
Mulder 1994 used a daily metered dose of GHK-Cu gel on diabetic foot ulcers, and the abstract does not give the strength. Median wound closure was 98.5% versus 60.8% with vehicle.[3]
Is GHK-Cu legal to compound or sell?
Not approved as a drug. FDA lists the non-injectable routes in Category 1 and the injectable route among the withdrawn Category 2 nominations. It is not in the HHS Appendix A. Cosmetic use is common.[24][25][26]
What is the difference between GHK and GHK-Cu?
GHK is the three amino acid chain. GHK-Cu is the same chain bound to copper. Much of the research mixes the two, so read labels carefully.[1][28]
How do I do the vial math for GHK-Cu?
Divide the vial amount by the liquid volume to get concentration, then divide the chosen amount by the concentration. The wiki example is 50 mg in 2 mL, which is 25 mg/mL. The reconstitution calculator does this without a preset dose.[19]
Is GHK-Cu in GLOW or KLOW, and at what amount?
GHK-Cu is reported as a component of several community blends. I found no sourced per-component amounts for any of them. See the blend pages for compositions.
Bottom line
GHK-Cu is a tripeptide that interests researchers for wound repair and skin remodeling, and its human record is thin. What is published: controlled skin trials with mixed results, a 0.4% cream that matched vehicle, a foot ulcer gel that outperformed vehicle without a stated strength in the abstract, and a cosmetic safety review at about 0.001%.[3][4][7] What is merely reported online: 1 to 2 mg daily injections, 4 to 8 week cycles and 1 to 3% serums.[19][20] What remains speculative: injected benefit, injected safety, any link between a rodent amount and a human one, and the 100 to 200 mg estimate in the Pickart reviews.[1][2] Status: not approved, with injectable use flagged by FDA for immunogenicity and an advisory committee review expected.[18][25]
Keep reading
Sources
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. BioMed Res Int. 2014;2014:151479. https://doi.org/10.1155/2014/151479 PMID 25302294. Authors list a Skin Biology R&D affiliation. Review of laboratory and animal work (Tier 3 and 4); industry-affiliated authors.
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Res Int. 2015;2015:648108. https://doi.org/10.1155/2015/648108 PMID 26236730. Review summarizing human facial studies; primary reports not located; industry-affiliated authors.
- Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair Regen. 1994;2(4):259-269. https://doi.org/10.1046/j.1524-475X.1994.20406.x PMID 17147644. Published human clinical trial (Tier 1). Read at abstract level.
- Bishop JB, Phillips LG, Mustoe TA, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-257. https://doi.org/10.1067/mva.1992.37086 PMID 1495150. Published human clinical trial (Tier 1). Read at abstract level.
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-259. https://doi.org/10.1001/archfaci.8.4.252 PMID 16847171. Published human clinical trial (Tier 1). Read at abstract level.
- Hostynek JJ, Dreher F, Maibach HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflamm Res. 2010;59(11):983-988. https://doi.org/10.1007/s00011-010-0214-4 PMID 20703511. Laboratory research (Tier 4).
- Johnson W Jr, Bergfeld WF, Belsito DV, et al. Safety assessment of tripeptide-1, hexapeptide-12, their metal salts and fatty acyl derivatives, and palmitoyl tetrapeptide-7 as used in cosmetics. Int J Toxicol. 2018;37(3 suppl):90S-102S. https://doi.org/10.1177/1091581818807863 No PMID located. Expert panel safety review (Tier 4). Abstract and metadata only; the 10 ppm figure applies to the ingredient group.
- Canapp SO, Farese JP, Schultz GS, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Vet Surg. 2003;32(6):515-523. PMID 14648529. Published animal research (Tier 3).
- Cangul IT, Gul NY, Topal A, Yilmaz R. Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits. Vet Dermatol. 2006;17(6):417-423. PMID 17083573. Published animal research (Tier 3).
- Fu SC, Cheuk YC, Chiu WYV, et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res. 2015;33(7):1024-1033. https://doi.org/10.1002/jor.22831 PMID 25731775. Published animal research (Tier 3).
- Ma WH, Li M, Ma HF, et al. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci. 2019;241:117139. https://doi.org/10.1016/j.lfs.2019.117139 PMID 31809714. Published animal research (Tier 3).
- Mazzola J, Rosenfeld M, Tucker M, Wezeman J, Ladiges W, Liao G. Middle-aged mice treated with GHK-Cu peptide administered intraperitoneally or intranasally show behavioral rescue but divergent hippocampal aging programs. Res Sq preprint, 26 May 2026. https://doi.org/10.21203/rs.3.rs-9520102/v1 PMID 42245779; PMC13232416. Published animal research (Tier 3). Preprint, not peer reviewed.
- Wang X, Liu B, Xu Q, et al. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair Regen. 2017;25(2):270-278. https://doi.org/10.1111/wrr.12520 PMID 28370978. Published animal research (Tier 3).
- Arul V, Kartha R, Jayakumar R. A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sci. 2006;80(4):275-284. https://doi.org/10.1016/j.lfs.2006.09.018 PMID 17049946. Published animal research (Tier 3).
- Tanaka Y, Aso T, Ono J, Hosoi R, Kaneko T. Androgenetic alopecia treatment in Asian men. J Clin Aesthet Dermatol. 2018;11(7):32-35. PMID 30057663; PMC6057731. Case series (Tier 2). Combination protocol.
- ClinicalTrials.gov. NCT07437586 (topical GHK-Cu gel versus vehicle on punch wounds, Phase 2, sponsor Hudson Biotech). https://clinicaltrials.gov/study/NCT07437586 Registered human trial (Tier 2). Recruiting; no results.
- ClinicalTrials.gov. NCT07706361 (patch effect on blood GHK and GHK-Cu levels). https://clinicaltrials.gov/study/NCT07706361 Registered human trial (Tier 2). Not yet recruiting.
- Stone W. Copper peptides are all over social media. NPR/WNYC, 7 September 2026. https://www.npr.org/2026/09/07/nx-s1-5955552/copper-peptides-skin-aging-health-safe Journalism quoting named experts; not a study.
- Peptide Protocol Wiki Team. GHK-Cu dosing. https://www.peptideprotocolwiki.com/peptides/ghk-cu/dosing Dated 29 January 2026 per the page. Community, vendor or clinic reported (Tier 6). No references listed; the site also lists vendors.
- Peptide Protocol Wiki Team. GHK-Cu community reports. https://www.peptideprotocolwiki.com/peptides/ghk-cu/community Community, vendor or clinic reported (Tier 6). Based on 90 community reports that are not individually attributed.
- Peptidepedia. GHK-Cu dosage. https://peptidepedia.org/aesthetics/ghk-cu/dosage Published 15 January 2025. Practitioner reported (Tier 5). Pharmacist-authored; carries an advertisement; six references not matched to figures.
- Peptide Dossier. GHK-Cu dosage guide. https://peptidedossier.com/guides/ghk-cu-dosage/ Educational site; states it does not sell peptides. Conflicting reports (rejects circulating figures).
- BSCG. GHK-Cu peptide benefits, safety, legal status and research. https://www.bscg.org/blogs/single/ghk-cu-peptide-benefits-safety-legal-status-and-research Published 31 July 2026. Conflicting reports. Certification company page; claims on the 503A list and WADA conflict with FDA and WADA documents.
- U.S. Food and Drug Administration. Categories of bulk drug substances nominated for 503A compounding (interim policy list), updated 14 May 2026. https://www.fda.gov/media/94155/download Regulator document.
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 and withdrawn nominations). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Regulator statement.
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Appendix B. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Regulator draft policy; non-binding.
- Federal Register notice 2026-22192, docket HHS-OASH-2026-0496 (public inspection copy). https://public-inspection.federalregister.gov/2026-22192.pdf Regulator notice.
- Wikipedia. Copper peptide GHK-Cu. https://en.wikipedia.org/wiki/Copper_peptide_GHK-Cu Secondary source (identifiers only). Confirm in a chemical database.
- Mao S, Huang J, Li J, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol. 2025;16:1551843. https://doi.org/10.3389/fphar.2025.1551843 PMID 40672369. Published animal research (Tier 3). Dose not in abstract.
Educational reference only, not medical advice. This page documents amounts and concentrations reported in published research and circulating online. It does not tell any reader what to use, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.